Medicare AdvantagePrior AuthMedium impact
Topical Tretinoin Containing Products (Revised)
Humana·Dermatology·Medicare Advantage
Effective date
Jan 1, 2021
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage has revised its prior authorization policy for topical tretinoin-containing products (effective 1/1/2021, revised 2/25/2026). The policy requires prior authorization for tretinoin products used to treat acne vulgaris and actinic keratosis, with approval covering the plan year duration for both initial and renewal requests. No substantive coverage changes are documented in this revision—this appears to be a routine policy reaffirmation.
Action Required
Immediately: Billing team must verify that all topical tretinoin product claims (Avita, Retin-A, Retin-A Micro, Atralin, Altreno, and generic tretinoin in all formulations) submitted to Humana Medicare Advantage plans require prior authorization before dispensing. Update billing system workflows to flag tretinoin prescriptions for prior auth submission. Providers should document diagnosis of either acne vulgaris or actinic keratosis on all prescriptions to support PA requests. Confirm current PA requirements through Humana's PAL (Preauthorization and Notification List) portal at www.humana.com/PAL. Claims submitted without prior authorization will be denied. Note: This policy was last revised 2/25/2026 (1 day old) and supersedes any older tretinoin coverage guidance.